Sangui BioTech International Inc.

Sangui BioTech International Inc.: Significant increase in sales in the first three quarters of the year – Further reduction of the operating loss

Sangui BioTech International Inc.: Significant increase in sales in the first half of the year – Further reduction of the operating loss

Sangui BioTech International Inc.: – Sales of USD 41,029 in first quarter – For the first time, positive quarterly result in the company’s history

Sangui BioTech International Inc.: Increase in sales in the first quarter of 121% – Highest quarterly sales in the company’s history

Sangui BioTech International Inc.: Sales of USD 69,190 in fiscal year 2022 – Reduction of the operating loss

Sangui BioTech International Inc.: – Increase in sales in the first nine months of the year – Further reduction of the operating loss

Sangui BioTech International Inc.: Significant increase in sales in the first half of the year – Further reduction of the operating loss

Sangui BioTech International Inc.: – Sales of USD 18,560 in first quarter – Reduction of the operating loss

Sangui BioTech International Inc.: Granulox is awarded the prestigious Prix Galien

Sangui BioTech International Inc.: – Sales of USD 65,582 in fiscal year 2021 – Reduction of the operating loss

Sangui BioTech International Inc.: – Granulox(R) – Follow up

Sangui BioTech International Inc.: – Significant increase in sales in the first nine months – Reduction of operating loss

Sangui BioTech International Inc.: Significant increase in sales in the first half year; Reduction of operating loss

Sangui BioTech International Inc.: Significant increase in sales in the first quarter; Reduction of operating loss

Sangui BioTech International Inc.: Sales of USD 28,915 in fiscal year 2020

Sangui BioTech International Inc.: United States Patent Office grants patent ‘Compositions for improved tissue oxygenation by peritoneal ventilation’

Sangui BioTech International Inc.: -Significant cost reductions in the first three quarters – Significant reduction of operating loss -Impairments caused by COVID – 19

Sangui BioTech International Inc.: Significant cost reductions in the first half – year; Significant reduction of operating loss

Sangui BioTech International Inc.: – Significant cost reductions in the first quarter; – Mölnlycke invests in warehouse capacities

Sangui BioTech International Inc.: Sales of USD 88,001 in fiscal year 2019

Sangui BioTech International Inc.: Sales of USD 63,429 in the first nine month

Sangui BioTech International Inc.: Patent granted to Sangui for possible Septic Shock treatment

Sangui BioTech International Inc.: – Sales of USD 55,367 in the first half-year; Strong year-end-business

Sangui BioTech International Inc.: – Sales of USD 11,272 in the first quarter – Mölnlycke takes over distribution of Granulox

Sangui BioTech International Inc.: Sales of USD 77,152 in fiscal year 2018; Costs and loss is further reduced

Sangui BioTech International Inc.: Revenues of USD 74,000 in fiscal year 2018; Introduction on the market of Granulox in Southeast Asia is proceeding according to plan; Foundation of Sangui Know-How – und Patentverwertungsgesellschaft mbH & Co. KG

Sangui BioTech International Inc.: World leader in wound care acquires SastoMed GmbH

Sangui BioTech International Inc.: – Granulox with the Annual Advanced Wound Care Award honored

Sangui BioTech International Inc.: – Sales of USD 65,273 in the first nine months, Costs and loss is further reduced

Sangui BioTech International Inc.: – Sales of USD 55,082 in the first half-year; – Costs and loss is further reduced